Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
B cell lymphomas often develop in the central nervous system (CNS). Although rituximab (RTX) has been widely used for most B cell lymphomas, the efficacy for CNS lymphomas has yet to be elucidated. A major concern is that RTX might not reach lymphoma lesions, and either the antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity might not substantially operate in the CNS environment. Here we investigated the potential usefulness of co-administering RTX and human serum intraventricularly in nude rats carrying human B cell lymphomas in the CNS. Raji, a CD20-positive lymphoma cell line, was inoculated into the cerebrum of F344 (rnu/rnu) nude rats. After several days, RTX and human serum were delivered into the ipsilateral lateral ventricle via a cannula. Intraventricularly administered RTX was localized specifically at the lymphoma lesions, indicating that RTX penetrated the ependymal layer of the lateral ventricle to reach the tumor lesion, where it specifically bound to the lymphoma cells. The combination of RTX and serum (n = 12), but not RTX alone (n = 13), significantly extended the survival of the rats (P = 0.049). Intraventricular administration of RTX and serum in a rat/human CNS lymphoma model might be a potential novel treatment for CNS lymphomas of B cell origin. Clinical trials are warranted.
Miyake
Yasuyuki
Y
Clinical and Experimental Hematology, Major of Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, 305-8575, Japan.
Okoshi
Yasushi
Y
Machino
Takayuki
T
Chiba
Shigeru
S
D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011923:Rats, Nude; D000069283:Rituximab; D044967:Serum / Q000378:metabolism*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
Blood. 2002 Feb 1;99(3):1038-43
11807010
Blood. 2000 Jun 15;95(12):3900-8
10845926
Jpn J Clin Oncol. 2008 May;38(5):373-80
18413337
J Clin Oncol. 2007 Apr 10;25(11):1350-6
17312328
EMBO J. 1988 Mar;7(3):711-7
2456210
J Exp Med. 1988 Jun 1;167(6):1975-80
3260267
Leukemia. 1998 Dec;12(12):2029-33
9844934
Glia. 1998 Apr;22(4):348-59
9517567
Int J Hematol. 2009 Jun;89(5):577-83
19353238
Cancer Sci. 2007 Sep;98(9):1368-72
17640305
J Immunol. 2003 Aug 1;171(3):1581-7
12874252
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):211-227
10837717
Pharm Res. 2005 Jul;22(7):1011-37
16028003
J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31
9270488
Clin Cancer Res. 2003 Dec 15;9(17):6567-71
14695162
Clin Cancer Res. 2009 Mar 15;15(6):1989-97
19276270
Mol Genet Metab. 2005 Sep-Oct;86(1-2):141-9
16006167
Clin Cancer Res. 2006 Jul 1;12(13):4027-35
16818702
Haematologica. 2004 Jun;89(6):753-4
15194546
Blood. 2002 Feb 15;99(4):1314-9
11830481
J Neurooncol. 2006 Jan;76(2):131-8
16284923
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45
18552383
Cancer Sci. 2006 Jan;97(1):80-3
16367925
Blood. 1994 Jan 15;83(2):435-45
7506951
Cell Immunol. 2000 Aug 25;204(1):55-63
11006018
J Immunol. 2001 Feb 15;166(4):2717-26
11160337
Cancer Immunol Immunother. 2002 Mar;51(1):15-24
11845256
Glia. 1998 Jan;22(1):72-85
9436789
Expert Rev Neurother. 2009 Oct;9(10):1497-509
19831839
Blood. 2003 Jan 15;101(2):466-8
12393404
Blood. 2004 Sep 15;104(6):1793-800
15172969
J Neurooncol. 1999 Jun;43(2):153-60
10533727
Leuk Lymphoma. 2001 Aug;42(4):731-8
11697503
Blood. 2003 Feb 1;101(3):949-54
12393572